MA56674B1 - Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci - Google Patents
Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ciInfo
- Publication number
- MA56674B1 MA56674B1 MA56674A MA56674A MA56674B1 MA 56674 B1 MA56674 B1 MA 56674B1 MA 56674 A MA56674 A MA 56674A MA 56674 A MA56674 A MA 56674A MA 56674 B1 MA56674 B1 MA 56674B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- macrocyclic compounds
- sting agonists
- compounds
- macrocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne des composés macrocycliques de Formule générale (I) ou (II) et leurs formes tautomères, des stéréoisomères, des sels pharmaceutiquement acceptables, des hydrates, des solvates et des promédicaments de ceux-ci, et leur combinaison avec un médicament approprié, des procédés correspondants pour la synthèse et des compositions pharmaceutiques et des utilisations des composés décrits dans l'invention.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029556 | 2019-07-22 | ||
| IN201921051086 | 2019-12-10 | ||
| IN202021003961 | 2020-01-29 | ||
| EP20768090.1A EP4004002B1 (fr) | 2019-07-22 | 2020-07-22 | Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci |
| PCT/IB2020/056875 WO2021014365A1 (fr) | 2019-07-22 | 2020-07-22 | Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56674B1 true MA56674B1 (fr) | 2024-09-30 |
Family
ID=72422197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56674A MA56674B1 (fr) | 2019-07-22 | 2020-07-22 | Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20220289763A1 (fr) |
| EP (1) | EP4004002B1 (fr) |
| JP (1) | JP7592689B2 (fr) |
| KR (1) | KR20220035955A (fr) |
| CN (1) | CN114174303B (fr) |
| AU (1) | AU2020319058A1 (fr) |
| BR (1) | BR112022001125A2 (fr) |
| CA (1) | CA3147397A1 (fr) |
| CL (1) | CL2022000145A1 (fr) |
| CO (1) | CO2022001814A2 (fr) |
| CR (1) | CR20220029A (fr) |
| DK (1) | DK4004002T3 (fr) |
| EC (1) | ECSP22005485A (fr) |
| ES (1) | ES2989915T3 (fr) |
| FI (1) | FI4004002T3 (fr) |
| GE (1) | GEP20247627B (fr) |
| HR (1) | HRP20241222T1 (fr) |
| HU (1) | HUE068456T2 (fr) |
| IL (1) | IL289740A (fr) |
| LT (1) | LT4004002T (fr) |
| MA (1) | MA56674B1 (fr) |
| MX (1) | MX2022000939A (fr) |
| PE (1) | PE20220937A1 (fr) |
| PH (1) | PH12022550175A1 (fr) |
| PL (1) | PL4004002T3 (fr) |
| PT (1) | PT4004002T (fr) |
| RS (1) | RS66126B1 (fr) |
| SA (1) | SA522431429B1 (fr) |
| SI (1) | SI4004002T1 (fr) |
| SM (1) | SMT202400399T1 (fr) |
| WO (1) | WO2021014365A1 (fr) |
| ZA (1) | ZA202201375B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114585623A (zh) | 2019-08-02 | 2022-06-03 | 梅尔莎纳医疗公司 | 双[N-((5-氨基甲酰基)-1H-苯并[d]咪唑-2-基)吡唑-5-甲酰胺]衍生物和相关化合物作为STING（干扰素基因刺激物）激动剂用于治疗癌症 |
| MX2022012304A (es) | 2020-04-02 | 2022-11-30 | Mersana Therapeutics Inc | Conjugados de anticuerpo-farmaco que comprenden agonistas de sting. |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| US20240116909A1 (en) * | 2021-01-12 | 2024-04-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel compounds useful as sting agonists and uses thereof |
| CA3207893A1 (fr) * | 2021-01-15 | 2022-07-21 | Seagen Inc. | Conjugues anticorps-medicament immunomodulateurs |
| WO2024130341A1 (fr) * | 2022-12-22 | 2024-06-27 | Aculeus Therapeutics Pty Ltd | Dérivés de benzimidazole pour la modulation du sting |
| WO2025012057A1 (fr) * | 2023-07-07 | 2025-01-16 | F. Hoffmann-La Roche Ag | Macrocycles pour le traitement d'une maladie auto-immune |
| WO2025017045A1 (fr) * | 2023-07-19 | 2025-01-23 | F. Hoffmann-La Roche Ag | Macrocycles pour le traitement d'une maladie auto-immune |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20010395A1 (it) | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
| AR046959A1 (es) | 2003-12-18 | 2006-01-04 | Tibotec Pharm Ltd | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio |
| US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| MY162174A (en) | 2005-10-07 | 2017-05-31 | Exelixis Inc | Azetidines mek inhibitors for the treatment of proliferative diseases |
| RU2008152195A (ru) | 2006-06-15 | 2010-07-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа |
| WO2008090570A1 (fr) | 2007-01-25 | 2008-07-31 | Panacea Biotec Ltd | Nouveaux antimicrobiens |
| TW201000447A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
| WO2011091446A1 (fr) * | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Composés chimiques |
| WO2012083053A2 (fr) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Composés anti-viraux |
| AU2013366974B2 (en) | 2012-12-28 | 2017-11-02 | Nippon Zoki Pharmaceutical Co., Ltd. | Cinnamic acid amide derivative |
| ES2692226T3 (es) * | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
| US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| US10844051B2 (en) | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
| CA3019628A1 (fr) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Amides heterocycliques utiles en tant que modulateurs de proteine |
| US11352353B2 (en) | 2016-05-27 | 2022-06-07 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound serving as FGFR4 inhibitor |
| EA036435B1 (ru) * | 2017-02-22 | 2020-11-10 | Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед | Гетероциклические амиды, пригодные в качестве модуляторов белков |
| WO2018234808A1 (fr) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Modulateurs à petites molécules de sting humain |
| EP3642184A1 (fr) | 2017-06-22 | 2020-04-29 | Curadev Pharma Limited | Modulateurs à petites molécules du sting humain |
| US20200172483A1 (en) | 2017-06-22 | 2020-06-04 | Curadev Pharma Limited | Heterocyclic small molecule modulators of human sting |
| WO2019023635A1 (fr) | 2017-07-27 | 2019-01-31 | Stingray Therapeutics, Inc. | Série de 3 h-imidazo(4,5-c)pyridine substituée et de 1h-pyrrolo(2,3-c)pyridine d'une nouvelle ectonucléotide pyrophosphatase/phosphodiestérase-1 (enpp1) et stimulateur pour un modulateur de gènes d'interféron (sting) en tant qu'agents immunothérapeutiques contre le cancer |
| AU2018311966A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Benzo[b]thiophene sting agonists for cancer treatment |
| EP3661499A4 (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme Corp. | Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b |
| JP7291130B2 (ja) | 2017-10-05 | 2023-06-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質 |
| EP3692033A1 (fr) * | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih |
| WO2020132582A1 (fr) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Agonistes de sting et leurs utilisations |
| PE20220169A1 (es) | 2019-03-28 | 2022-01-28 | Lupin Ltd | Compuestos macrociclicos como agonistas de sting |
-
2020
- 2020-07-22 PT PT207680901T patent/PT4004002T/pt unknown
- 2020-07-22 ES ES20768090T patent/ES2989915T3/es active Active
- 2020-07-22 PE PE2022000120A patent/PE20220937A1/es unknown
- 2020-07-22 LT LTEPPCT/IB2020/056875T patent/LT4004002T/lt unknown
- 2020-07-22 RS RS20241052A patent/RS66126B1/sr unknown
- 2020-07-22 HU HUE20768090A patent/HUE068456T2/hu unknown
- 2020-07-22 FI FIEP20768090.1T patent/FI4004002T3/fi active
- 2020-07-22 GE GEAP202015883A patent/GEP20247627B/en unknown
- 2020-07-22 BR BR112022001125A patent/BR112022001125A2/pt unknown
- 2020-07-22 PH PH1/2022/550175A patent/PH12022550175A1/en unknown
- 2020-07-22 CR CR20220029A patent/CR20220029A/es unknown
- 2020-07-22 SI SI202030501T patent/SI4004002T1/sl unknown
- 2020-07-22 US US17/628,619 patent/US20220289763A1/en active Pending
- 2020-07-22 KR KR1020227005943A patent/KR20220035955A/ko active Pending
- 2020-07-22 CA CA3147397A patent/CA3147397A1/fr active Pending
- 2020-07-22 JP JP2022504707A patent/JP7592689B2/ja active Active
- 2020-07-22 SM SM20240399T patent/SMT202400399T1/it unknown
- 2020-07-22 MX MX2022000939A patent/MX2022000939A/es unknown
- 2020-07-22 WO PCT/IB2020/056875 patent/WO2021014365A1/fr active Application Filing
- 2020-07-22 PL PL20768090.1T patent/PL4004002T3/pl unknown
- 2020-07-22 MA MA56674A patent/MA56674B1/fr unknown
- 2020-07-22 CN CN202080053237.XA patent/CN114174303B/zh active Active
- 2020-07-22 HR HRP20241222TT patent/HRP20241222T1/hr unknown
- 2020-07-22 EP EP20768090.1A patent/EP4004002B1/fr active Active
- 2020-07-22 AU AU2020319058A patent/AU2020319058A1/en active Pending
- 2020-07-22 DK DK20768090.1T patent/DK4004002T3/da active
-
2022
- 2022-01-10 IL IL289740A patent/IL289740A/en unknown
- 2022-01-19 SA SA522431429A patent/SA522431429B1/ar unknown
- 2022-01-21 CL CL2022000145A patent/CL2022000145A1/es unknown
- 2022-01-21 EC ECSENADI20225485A patent/ECSP22005485A/es unknown
- 2022-01-28 ZA ZA2022/01375A patent/ZA202201375B/en unknown
- 2022-02-21 CO CONC2022/0001814A patent/CO2022001814A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56674B1 (fr) | Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci | |
| MA29685B1 (fr) | Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques | |
| MA58004B1 (fr) | Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux | |
| MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA44721A (fr) | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
| MA45153B1 (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| TNSN08445A1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| MA38175A1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA33364B1 (fr) | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine | |
| MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA30916B1 (fr) | Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine | |
| MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique |